Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration
Europe's medicines regulator said on Thursday it had added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's (JNJ.N) COVID-19 vaccine after it reviewed 108 cases reported worldwide.
"After assessing the available data, PRAC considered that a causal relationship between COVID-19 vaccine Janssen and GBS is possible," the European Medicines Agency said, referring to its safety committee, PRAC.
Reporting by Pushkala Aripaka in Bengaluru; editing by Uttaresh.V